Quality of life results in the UK TACT2 Trial of accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer: a multicentre, phase 3, open-label, randomised, controlled trial (CRUK/05/19)

Bliss, J

dc.contributor.author	Bliss, J
dc.date.accessioned	2023-11-23T10:50:35Z
dc.date.available	2023-11-23T10:50:35Z
dc.identifier.citation	The Lancet Oncology,	en_US
dc.identifier.issn	1213-9432
dc.identifier.uri	https://repository.icr.ac.uk/handle/internal/6064
dc.language.iso	eng	en_US
dc.publisher	Elsevier	en_US
dc.relation.ispartof	The Lancet Oncology
dc.rights.uri	https://creativecommons.org/licenses/by-nc-nd/4.0/	en_US
dc.title	Quality of life results in the UK TACT2 Trial of accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer: a multicentre, phase 3, open-label, randomised, controlled trial (CRUK/05/19)	en_US
dc.type	Journal Article
dcterms.dateAccepted	2023-09-12
dc.date.updated	2023-11-14T14:25:24Z
rioxxterms.version	VoR	en_US
rioxxterms.type	Journal Article/Review	en_US
pubs.organisational-group	ICR
pubs.organisational-group	ICR/Primary Group
pubs.organisational-group	ICR/Primary Group/ICR Divisions
pubs.organisational-group	ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group	ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.publication-status	Accepted
icr.researchteam	Clin Trials & Stats Unit	en_US
dc.contributor.icrauthor	Bliss, Judith
icr.provenance	Deposited by Mrs Jessica Perry (impersonating Prof Judith Bliss) on 2023-11-14. Deposit type is initial. No. of files: 1. Files: Quality of life results in the UK TACT2 Trial of accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer.pdf